Dataset Information

Elevated plasma sTIM-3 levels in patients with severe COVID-19.

ABSTRACT:

Background

The pathogenesis of coronavirus disease 2019 (COVID-19) is still incompletely understood, but it seems to involve immune activation and immune dysregulation.

Objective

We examined the parameters of activation of different leukocyte subsets in COVID-19-infected patients in relation to disease severity.

Methods

We analyzed plasma levels of myeloperoxidase (a marker of neutrophil activation), soluble (s) CD25 (sCD25) and soluble T-cell immunoglobulin mucin domain-3 (sTIM-3) (markers of T-cell activation and exhaustion), and sCD14 and sCD163 (markers of monocyte/macrophage activation) in 39 COVID-19-infected patients at hospital admission and 2 additional times during the first 10 days in relation to their need for intensive care unit (ICU) treatment.

Results

Our major findings were as follows: (1) severe clinical outcome (ICU treatment) was associated with high plasma levels of sTIM-3 and myeloperoxidase, suggesting activated and potentially exhausted T cells and activated neutrophils, respectively; (2) in contrast, sCD14 and sCD163 showed no association with need for ICU treatment; and (3) levels of sCD25, sTIM-3, and myeloperoxidase were inversely correlated with degree of respiratory failure, as assessed by the ratio of Pao₂ to fraction of inspired oxygen, and were positively correlated with the cardiac marker N-terminal pro-B-type natriuretic peptide.

Conclusion

Our findings suggest that neutrophil activation and, in particular, activated T cells may play an important role in the pathogenesis of COVID-19 infection, suggesting that T-cell-targeted treatment options and downregulation of neutrophil activation could be of importance in this disorder.

SUBMITTER: Ueland T

PROVIDER: S-EPMC7503135 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Elevated plasma sTIM-3 levels in patients with severe COVID-19.

Ueland Thor T Heggelund Lars L Lind Andreas A Holten Aleksander R AR Tonby Kristian K Michelsen Annika E AE Jenum Synne S Jørgensen Marthe J MJ Barratt-Due Andreas A Skeie Linda G LG Nordøy Ingvild I Aanensen Fraz Mai Sasaki MS Quist-Paulsen E Else E Pischke Søren E SE Johal Simreen K SK Hesstvedt Liv L Bogen Mette M Fevang Børre B Halvorsen Bente B Müller Fredrik F Bekken Gry Kloumann GK Mollnes Tom E TE Dudman Susanne S Aukrust Pål P Dyrhol-Riise Anne M AM Holter Jan C JC

The Journal of allergy and clinical immunology 20200921 1

<h4>Background</h4>The pathogenesis of coronavirus disease 2019 (COVID-19) is still incompletely understood, but it seems to involve immune activation and immune dysregulation.<h4>Objective</h4>We examined the parameters of activation of different leukocyte subsets in COVID-19-infected patients in relation to disease severity.<h4>Methods</h4>We analyzed plasma levels of myeloperoxidase (a marker of neutrophil activation), soluble (s) CD25 (sCD25) and soluble T-cell immunoglobulin mucin domain-3 ...[more]

PMID: 32971109

Similar Datasets

Project description:Background & aimsEndothelial injury and dysfunction play a detrimental role in the pathogenesis of infections. Endothelium-related molecules have been reported as potential diagnostic and/or prognostic biomarkers of infection. The prognostic value of these biomarkers in patients with cirrhosis and infections remains elusive.MethodsIn this study, we investigated the performance of key soluble endothelial injury biomarkers, including intercellular adhesion molecule 1 (ICAM1), von Willebrand factor (vWF), vascular endothelial growth factor receptor 1 (VEGFR1), and angiopoietin 1 and 2 (Ang1, 2) as mortality predictors in patients with cirrhosis and severe COVID-19 or bacterial sepsis.ResultsA total of 66 hospitalized patients (admitted to the COVID-19 ward or liver intensive care unit [ICU]) were included. Twenty-two patients had COVID-19 alone, while 20 patients had cirrhosis plus COVID-19. Twenty-four patients had cirrhosis plus bacterial sepsis. Among patients with cirrhosis, the most common aetiology of liver disease was alcohol. ICAM1 was increased (p = 0.003) while VEGFR1 (p <0.0001) and Ang1 (p <0.0001) were reduced in patients with COVID-19 and cirrhosis, compared to patients with COVID-19 alone. Endothelial biomarker levels did not differ significantly between patients with cirrhosis and severe COVID-19 or bacterial sepsis in the ICU. In these patients, ICAM1 levels significantly and independently predicted mortality (hazard ratio 3.24; 95% CI 1.19-8.86) along with model for end-stage liver disease (MELD) score, renal and coagulation failures. The AUC for ICAM1 was 0.74, MELD was 0.60 and combined ICAM1 and MELD was 0.70. ICAM1 also positively correlated with the composite organ failure scores recorded 3-5 days post ICU admission (CLIF-OF and SOFA) in this subgroup of patients.ConclusionThe study indicates that in patients with cirrhosis, elevated plasma ICAM1 serves as an independent predictor of severe COVID-19- or sepsis-associated 28-day mortality.Lay summaryBacterial sepsis and COVID-19 lead to increased mortality in patients with cirrhosis. In this study, we demonstrate that high plasma levels of ICAM1, an endothelial injury biomarker, is one of the important factors predicting mortality in critically ill cirrhotic patients with severe COVID-19 or bacterial sepsis.

Dataset Information

Elevated plasma sTIM-3 levels in patients with severe COVID-19.

Background

Objective

Methods

Results

Conclusion

Publications

Elevated plasma sTIM-3 levels in patients with severe COVID-19.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets